Search - tctmd.com

Displaying 61 - 80 of 133

Sort: Relevancy | Date

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

News Daily News

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

December 02, 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

News Daily News

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

April 08, 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

News Conference News EHRA 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

March 21, 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presentation ACC 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presenter: Renato Lopes

March 18, 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

March 17, 2019

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

March 12, 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

March 11, 2019

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

News Daily News

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

March 08, 2019

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

News Daily News

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

February 25, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

The Biggest News of 2018: TCTMD’s Top 10

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

December 31, 2018

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

October 04, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.